The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
Crossref DOI link: https://doi.org/10.1186/1546-0096-12-S1-P76
Published Online: 2014-09-17
Published Print: 2014-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Leinonen, Mika
Hallén, Bengt
Olivecrona, Hans
Article History
First Online: 17 September 2014